Research programme: respiratory syncytial virus fusion inhibitors - Bristol-Myers Squibb

Drug Profile

Research programme: respiratory syncytial virus fusion inhibitors - Bristol-Myers Squibb

Alternative Names: BMS-433771; BMS-505321

Latest Information Update: 18 Jan 2008

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antivirals; Benzimidazoles; Oximes; Small molecules
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Respiratory syncytial virus infections

Most Recent Events

  • 02 Feb 2006 Data presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2005) have been added to the Viral Infections antimicrobial activity section
  • 22 Sep 2005 This programme is still in active development - 230th American Chemical Society National Meeting (230th-ACS-2005)
  • 06 Dec 2002 Preclinical trials in Respiratory syncytial virus infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top